• Endogenous TNF superfamily ligands are either active as membrane-form (e.g. FasL, TRAIL, CD40L, OX40L) or are secreted and activated through oligomerization by the binding of proteoglycans at the surface of cells (e.g. APRIL).
• MultimericLigands™ are constructs in which two trimeric TNFSF ligands are linked via the oligomeric collagen domain of Adiponectin [ACRP30headless].
• MultimericLigands™ mimic the membrane-bound forms of the proteins and show high activity.

• For in vitro studies!

Potent B cell and T cell expansion tool for Cell Therapy Application.

Accelerates ex-vivo TIL expansion for Immunotherapy.

Potent B cell and T cell expansion tool for Cell Therapy Application.

Accelerates ex-vivo TIL expansion for Immunotherapy.

Produced using animal component-free medium in characterized and certified CHO cells.

GMP-like production.

Ex vivo B Cell Expansion for Cell Therapy.

• The avidity (binding) and activity of selected proteins are improved by the addition of an oligomerization domain fused at the N- or C-terminus of the protein of interest.
• COMP-Fusion Proteins are based on the pentamerization domain (minimal coiled-coil domain) of the cartilage oligomeric matrix protein (COMP) which is fused through a specific linker to proteins of interest.
• Using this technology AdipoGen Life Sciences generates cytokines with improved avidity and biological activity.

• For in vitro and in vivo studies!

• The knobs-into-holes (KIH) strategy is a pioneering format, permitting heavy-chain heterodimerization to create an “IgG with two different arms”.
• The KIH technology can also be used for protein engineering.
• AdipoGen Life Sciences developed various interleukins (e.g. IL-2, IL-33 and IL-38) into an Fc-fusion protein using the KIH technology.
• The KIH proteins are monomeric (see Figure) with greatly enhanced stability and substantially improved pharmacokinetics (PK) while maintaining cytokine activity.
• AdipoGen Life Sciences also developed heterodimeric proteins using the KIH-technology.
• These special monomeric Fc-constructs are produced in mammalian cells with low endotoxin content.

• For in vitro and in vivo studies!

• The monomeric IL-2 proteins, including the IL-2 (human) (monomeric):Fc-KIH (human) (rec.) (#AG-40B-0224), IL-2 (mouse) (monomeric):Fc-KIH (human) (rec.) (#AG-40B-0225) and IL-2 Superkine (monomeric):Fc-KIH (human) (rec.) (#AG-40B-0222) are activity tested and compared to a dimeric Fc fusion protein IL-2 Superkine (Fc) (#AG-40B-0111), all produced in mammalian cells with low endotoxin content. Activation of IL-2R is analyzed using the IL-2 Bioassay from Promega (#JA2201) consisting of a genetically engineered cell line expressing the IL-2R. When IL-2 binds to its receptor (IL-2R), receptor-mediated pathway signaling induces luminescence that is measured with a luminometer. The experiment shows a several-fold increased activity of the monomeric constructs.

• Fc-Fusion proteins (also known as Fc-Chimeric Fusion proteins, Ig-based Chimeric Fusion proteins and Fc-tag proteins) are composed of the Fc domain of IgG genetically linked to a protein of interest. Dimeric structures are formed during the production in mammalian cells.
• The fusion of a cytokine sequence to the Fc domain of an IgG (human or mouse) determines a prolonged circulating half-life time in vivo.
• The Fc domain folds independently and can improve the solubility and stability of the partner molecule both in vitro and in vivo.

• Non-lytic: Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody-directed cytotoxicity (ADCC) and complement-directed cytotoxicity (CDC).

• For in vitro and especially in vivo studies!

More Information

Downloadable Flyer

Proteins with Enhanced Activity & Stability - Mini-Catalog

AdipoGen Life Sciences specializes in the development of recombinant proteins that show enhanced activity and long half-life, produced in mammalian cells. Using proprietary in-house technologies together with established and published technologies, we engineer, develop and produce an innovative panel of recombinant proteins for different research fields including Cell Therapy Research.

Includes:

For more information visit AdipoGen Life Sciences' landing page Proteins with Enhanced Activity & Stability.

Released - April 2023

Download PDF